Different structural alterations upregulate in vitro tyrosine kinase activity and transforming potency of the erbB-2 gene.
Open Access
- 1 December 1988
- journal article
- research article
- Published by Taylor & Francis in Molecular and Cellular Biology
- Vol. 8 (12) , 5570-5574
- https://doi.org/10.1128/mcb.8.12.5570
Abstract
Compared with normal erbB-2 gp185, mutant erbB-2 proteins generated by mutations either in the transmembrane domain or by NH2-terminal deletion are able to transform NIH 3T3 cells at a 10- to 100-fold greater efficiency. Mutant proteins of both classes show increased tyrosine kinase activity, suggesting that an abnormal level of receptor-associated tyrosine kinase activity is a major determinant of erbB-2 oncogenic potential.This publication has 25 references indexed in Scilit:
- erb B-2 Is a Potent Oncogene When Overexpressed in NIH/3T3 CellsScience, 1987
- Epidermal growth factor induces rapid, reversible aggregation of the purified epidermal growth factor receptorBiochemistry, 1987
- Self-phosphorylation of epidermal growth factor receptor: evidence for a model of intermolecular allosteric activationBiochemistry, 1987
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu OncogeneScience, 1987
- Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185Cell, 1986
- Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptorNature, 1986
- The neu oncogene encodes an epidermal growth factor receptor-related proteinNature, 1986
- Tyrosine Kinase Receptor with Extensive Homology to EGF Receptor Shares Chromosomal Location with neu OncogeneScience, 1985
- Amplification of a Novel v- erb B-Related Gene in a Human Mammary CarcinomaScience, 1985
- Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblastsNature, 1981